Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III TrialShukui Qin, Chunyi Hao, Zhendong Chen et al.|Journal of Clinical Oncology|2022Cited by 191
Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Lin Shen, Jia Wei et al.|Clinical Cancer Research|2021Cited by 119
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.Shukui Qin, Chunyi Hao, Zhendong Chen et al.|Journal of Clinical Oncology|2022Cited by 111
Data from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Lin Shen, Wei Jia et al.|Unknown|2023Cited by 0
Data from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Lin Shen, Wei Jia et al.|Unknown|2023Cited by 0